Four years experience of primary intra-arterial chemotherapy (PIAC) for locally advanced and recurrent breast cancer.

Maurizio Cantore, F Smerieri, Giovanna Cavazzini(University of Padua), D. Zamagni, G Caleffi, Giammaria Fiorentini(Ospedali Riuniti Marche Nord), Andrea Mambrini, Marco Caforio, C Morandi(Music Conservatory of Mantova), L Molani

PubMed

September 1, 1997

Cited by 5

Related Papers

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

|The Lancet Oncology|2020|322

Trends and challenges in the operation of pumped-storage hydropower plants

|Renewable and Sustainable Energy Reviews|2015|315

Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

|Annals of Oncology|2019|282

A new generation of small hydro and pumped-hydro power plants: Advances and future challenges

|Renewable and Sustainable Energy Reviews|2014|273

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

|The Lancet|2015|202